Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06480552 | An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors | PHASE1 | RECRUITING | 240 | — | — | Jul 22, 2024 | Feb 25, 2031 | Feb 5, 2026 | 11 | United States, Canada |
CTCAE: Common Terminology Criteria for Adverse Events
DLT: dose-limiting toxicity
RECIST: Response Evaluation Criteria in Solid Tumors.
| Arm | Type | Description |
|---|---|---|
| TEV-56278 Monotherapy; Dose Escalation | EXPERIMENTAL | - |
| TEV-56278 Monotherapy; Dose Expansion | EXPERIMENTAL | - |
| TEV-56278 in Combination with Pembrolizumab; Dose Escalation | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| TEV-56278 | DRUG | Administered intravenously |
| Pembrolizumab | DRUG | Administered intravenously |
Inclusion Criteria: * Have an established histological diagnosis of selected solid tumor and must have received and progressed on established standard therapies or have been intolerant to such therapy or have been considered by the Investigator as ineligible for approved standard therapy * Have a l...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |